Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836935 | 0.85 | FUCA1 (0.40) | FUCA1MTNR1ACACNA1HSLC6A2SLC6A4 | |
| SCHEMBL24133924 | 0.77 | FUCA1 (0.38) | FUCA1MTNR1ACACNA1HGLAMTNR1B | |
| SCHEMBL15461396 | 0.77 | NAMPT (0.40) | FUCA1MTNR1ACACNA1H | |
| SCHEMBL31678251 | 0.77 | NAMPT (0.40) | FUCA1MTNR1ACACNA1H | |
| SCHEMBL3394009 | 0.72 | NPC1 (0.43) | FUCA1MTNR1ACACNA1HMTNR1B | |
| SCHEMBL15461404 | 0.72 | FUCA1 (0.41) | FUCA1MTNR1ACACNA1HGLAMTNR1B | |
| SCHEMBL25608137 | 0.71 | FUCA1 (0.38) | FUCA1MTNR1ACACNA1HSLC6A2SLC6A4 | |
| SCHEMBL25045276 | 0.71 | HTR2C (0.34) | — | |
| SCHEMBL24015490 | 0.71 | MTNR1A (0.32) | FUCA1MTNR1ACACNA1HSLC6A2SLC6A4 | |
| SCHEMBL24015545 | 0.71 | MTNR1A (0.32) | FUCA1MTNR1ACACNA1HSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | Bugworks Research, Inc. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167119-A1 | DIAMINOPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBONITRILE COMPOUNDS AS ADENOSINE 2A RECEPTOR AND ADENOSINE 2B RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | FUCA1 4422/4885MTNR1A 95/4885CACNA1H 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.